Unknown

Dataset Information

0

A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.


ABSTRACT: The development of non-genotoxic therapies that activate wild-type p53 in tumors is of great interest since the discovery of p53 as a tumor suppressor. Here we report the identification of over 100 small-molecules activating p53 in cells. We elucidate the mechanism of action of a chiral tetrahydroindazole (HZ00), and through target deconvolution, we deduce that its active enantiomer (R)-HZ00, inhibits dihydroorotate dehydrogenase (DHODH). The chiral specificity of HZ05, a more potent analog, is revealed by the crystal structure of the (R)-HZ05/DHODH complex. Twelve other DHODH inhibitor chemotypes are detailed among the p53 activators, which identifies DHODH as a frequent target for structurally diverse compounds. We observe that HZ compounds accumulate cancer cells in S-phase, increase p53 synthesis, and synergize with an inhibitor of p53 degradation to reduce tumor growth in vivo. We, therefore, propose a strategy to promote cancer cell killing by p53 instead of its reversible cell cycle arresting effect.

SUBMITTER: Ladds MJGW 

PROVIDER: S-EPMC5856786 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2007-01-01 | S-EPMC1907109 | BioStudies
1000-01-01 | S-EPMC4516315 | BioStudies
2020-01-01 | S-EPMC7007433 | BioStudies
2020-01-01 | S-EPMC7566478 | BioStudies
2016-01-01 | S-EPMC5150668 | BioStudies
2017-01-01 | S-EPMC5762515 | BioStudies
2011-01-01 | S-EPMC3759979 | BioStudies
2019-01-01 | S-EPMC6760220 | BioStudies
2021-01-01 | S-EPMC7839369 | BioStudies
2021-01-01 | S-EPMC7957697 | BioStudies